Upharmacia August 2017
PHARMA MARKET NEWS
I nterchem
L ocalized
M anufacturing
in K azakhstan
Ukrainian company Interchem
reached agreement on localization
of manufacturing of its three drugs
at the facilities of Kazakh company
Viva Pharm in Almaty. The plant
will produce antiviral drug Tilaxin
(tilorone), anxiolytic Gidazepam VIC
(hydazepam) and opioid analgesic
Morphine sulfate VIC (morphine).
Medical director of Viva Pharm
stated that the companies striving
to localize another range of drugs.
The cooperation was stimulated
through government policy to
support local manufacturing
providing that the transfer of
production technologies in
Kazakhstan is more profitable than
the import of finished medicines.
“Kazakhstan’s pharmaceutical
market is developing dynamically,”
Deputy GM of Interchem said.
“Considering state policy of
Kazakhstan on stimulation of
local pharmaceutical production,
we decided to arrange the
manufacturing of demanded
drugs there. We have found the
partner, which we sure would
ensure a consistently high quality
of products.”
Moreover, in Aug, Interchem
entered the sports nutrition
market with three products: BCAA,
creatine, L-carnitine. All products
are presented under the name
SMARTPIT®.
In 2016, Interchem was 25th
company on Ukrainian retail drug
market by sales.
6
A cino W ill
R epresent 9
M edicines of M erck
in CIS and M oldova
Swizz company Acino reached
distribution agreement with Merck
to represent 9 medicines against
cardiovascular and endocrine
diseases. Since Jan 1, 2018, these
drugs will be available in Ukraine,
Armenia, Azerbaijan, K